Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2012.03.050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibacterial Activity of Nanostructured Zinc Oxide Tetrapods.
Int J Mol Sci
February 2023
Institute for Infection Medicine, University Medical Center Schleswig-Holstein, Christian-Albrecht University of Kiel, 24105 Kiel, Germany.
Zinc oxide (ZnO) tetrapods as microparticles with nanostructured surfaces show peculiar physical properties and anti-infective activities. The aim of this study was to investigate the antibacterial and bactericidal properties of ZnO tetrapods in comparison to spherical, unstructured ZnO particles. Additionally, killing rates of either methylene blue-treated or untreated tetrapods and spherical ZnO particles for Gram-negative and Gram-positive bacteria species were determined.
View Article and Find Full Text PDFAntioxidants in single methylene-blue-treated plasma units cannot be used to predict pathogen inactivation treatment success.
Vox Sang
July 2022
Blood Service, Belgian Red Cross, Namur, Belgium.
Background And Objectives: Measurement of antioxidant power (AOP) can be useful to validate the execution of the pathogen inactivation (PI) treatment of plasma units. The aim of this study was to evaluate the Theraflex technology for plasma units routinely used in Belgium.
Materials And Methods: AOP was tested on plasma units treated by Theraflex with various non-complete treatment scenarios.
ABO group-based strategy for inventory management of methylene blue-treated thawed plasma in a blood bank.
Transfus Apher Sci
October 2022
Haematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain.
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
Lancet Respir Med
March 2022
Fight AIDS and Infectious Diseases Foundation, Badalona, Spain; Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Universitat de Vic-Universitat Central de Catalunya, Vic, Spain; Lihir Medical Centre, International SOS, Lihir Island, Papua New Guinea.
Background: Convalescent plasma has been proposed as an early treatment to interrupt the progression of early COVID-19 to severe disease, but there is little definitive evidence. We aimed to assess whether early treatment with convalescent plasma reduces the risk of hospitalisation and reduces SARS-CoV-2 viral load among outpatients with COVID-19.
Methods: We did a multicentre, double-blind, randomised, placebo-controlled trial in four health-care centres in Catalonia, Spain.
Evaluation of the hemostatic capacity of methylene blue-treated liquid (not frozen) plasma stored up 14 days at 2° to 6°C.
Transfusion
August 2021
NHS Blood and Transplant and Barts Health NHS Trust, Queen Mary University of London, London, UK.
Background: Early plasma transfusion for management of bleeding, particularly trauma, is associated with better outcomes. Improving the availability/safety of plasma transfusion for patients is essential for transfusion services. The aim of this study is to evaluate the hemostatic capacity of methylene-blue (MB) liquid (not frozen) plasma over time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!